Login to Your Account



iTeos' Small-Molecule Approach Adds to Immunotherapy Arsenal

By Jennifer Boggs
Managing Editor

Wednesday, August 8, 2012

Nearly 20 years of work in cancer immunotherapy finally scored two big regulatory wins in recent years, with the approvals of Dendreon Corp.'s prostate cancer vaccine Provenge (sipuleucel-T) and Bristol-Myers Squibb Co.'s melanoma drug Yervoy (ipilimumab), but there is plenty of room for new approaches before the immunotherapy space reaches its full potential.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription